Arcadia Biosciences, Inc. (RKDA) Return on equity 2017–2025
Arcadia Biosciences, Inc. (RKDA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-56.5%FY2025 · since FY2017: -196.2% → -56.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -56.5% | +56.6 pp |
| FY2024 | -113.1% | -4.2 pp |
| FY2023 | -108.9% | -35.8 pp |
| FY2022 | -73.1% | -26.0 pp |
| FY2021 | -47.1% | -30.4 pp |
| FY2020 | -16.8% | +357.1 pp |
| FY2019 | -373.8% | -268.7 pp |
| FY2018 | -105.2% | +91.0 pp |
| FY2017 | -196.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RKDA financial trends
RKDA RevenueRKDA Net incomeRKDA Net marginRKDA Gross profitRKDA Gross marginRKDA Operating incomeRKDA Operating marginRKDA Operating cash flowRKDA Free cash flowRKDA Capital expendituresRKDA Stock buybacksRKDA Dividends paidRKDA Total assetsRKDA Total liabilitiesRKDA Shareholders’ equityRKDA overview →